Academic Radiology
Volume 16, Issue 9 , Pages 1108-1133 , September 2009

Molecular PET/CT Imaging-Guided Radiation Therapy Treatment Planning

Received 24 December 2008 ,Accepted 19 February 2009.

References 

  1. Cherry SR. In vivo molecular and genomic imaging: new challenges for imaging physics. Phys Med Biol. 2004;49:R13–R48
  2. Zaidi H, Alavi A. Current trends in PET and combined (PET/CT and PET/MR) systems design. PET Clin. 2007;2:109–123
  3. von Schulthess GK, Steinert HC, Hany TF. Integrated PET/CT: current applications and future directions. Radiology. 2006;238:405–422
  4. Juweid ME, Cheson BD. Positron-emission tomography and assessment of cancer therapy. N Engl J Med. 2006;354:496–507
  5. Blodgett TM, Meltzer CC, Townsend DW. PET/CT: form and function. Radiology. 2007;242:360–385
  6. Czernin J, Allen-Auerbach M, Schelbert HR. Improvements in cancer staging with PET/CT: literature-based evidence as of september 2006. J Nucl Med. 2007;48:78S–88S
  7. Townsend DW. Positron emission tomography/computed tomography. Sem Nucl Med. 2008;38:152–166
  8. Hasegawa B, Zaidi H. Dual-modality imaging: more than the sum of its components. In:  Zaidi H editors. Quantitative analysis in nuclear medicine imaging. New York: Springer; 2006;p. 35–81
  9. Goerres GW, von Schulthess GK, Steinert HC. Why most PET of lung and head-and-neck cancer will be PET/CT. J Nucl Med. 2004;45:66S–71S
  10. Zaidi H, Montandon M-L, Alavi A. Advances in attenuation correction techniques in PET. PET Clin. 2007;2:191–217
  11. Zaidi H, Montandon M-L. Scatter compensation techniques in PET. PET Clin. 2007;2:219–234
  12. Soret M, Bacharach SL, Buvat I. Partial-volume effect in PET tumor imaging. J Nucl Med. 2007;48:932–945
  13. Zaidi H, El Naqa I. PET-guided delineation of radiation therapy treatment volumes: a review of image segmentation techniques. Med Image Anal. In press.
  14. Bortfeld T. IMRT: a review and preview. Phys Med Biol. 2006;51:R363–R379
  15. Ling CC, Yorke E, Fuks Z. From IMRT to IGRT: frontierland or neverland?. Radiother Oncol. 2006;78:119–122
  16. Bentzen SM. Theragnostic imaging for radiation oncology: dose-painting by numbers. Lancet Oncol. 2005;6:112–117
  17. Bentzen SM. Dose painting and theragnostic imaging: towards the prescription, planning and delivery of biologically targeted dose distributions in external beam radiation oncology. Cancer Treat Res. 2008;139:41–62
  18. Chapman JD, Bradley JD, Eary JF, et al. Molecular (functional) imaging for radiotherapy applications: an RTOG symposium. Int J Radiat Oncol Biol Phys. 2003;55:294–301
  19. Grosu AL, Wiedenmann N, Molls M. Biological imaging in radiation oncology. Z Med Phys. 2005;15:141–145
  20. Messa C, Di Muzio N, Picchio M, et al. PET/CT and radiotherapy. Q J Nucl Med Mol Imaging. 2006;50:4–14
  21. Gregoire V, Haustermans K, Geets X, et al. PET-based treatment planning in radiotherapy: a new standard?. J Nucl Med. 2007;48:68S–77S
  22. Lecchi M, Fossati P, Elisei F, et al. Current concepts on imaging in radiotherapy. Eur J Nucl Med Mol Imaging. 2008;35:821–837
  23. Mah D, Chen CC. Image guidance in radiation oncology treatment planning: the role of imaging technologies on the planning process. Sem Nucl Med. 2008;38:114–118
  24. Xing L, Wessels B. The value of PET/CT is being over-sold as a clinical tool in radiation oncology. Med Phys. 2005;32:1457–1459
  25. Pan T, Chen L, Orton CG. PET/CT will become standard practice for radiotherapy simulation and planning. Med Phys. 2008;35:3825–3827
  26. Ollers M, Bosmans G, van Baardwijk A, et al. The integration of PET-CT scans from different hospitals into radiotherapy treatment planning. Radiother Oncol. 2008;87:142–146
  27. Aristophanous M, Penney BC, Pelizzari CA. The development and testing of a digital PET phantom for the evaluation of tumor volume segmentation techniques. Med Phys. 2008;35:3331–3342
  28. Bernier J, Hall EJ, Giaccia A. Radiation oncology: a century of achievements. Nat Rev Cancer. 2004;4:737–747
  29. Webb S, Evans PM. Innovative techniques in radiation therapy: editorial, overview, and crystal ball gaze to the future. Semin Radiat Oncol. 2006;16:193–198
  30. Perez CA, Purdy JA, Harms W, et al. Three-dimensional treatment planning and conformal radiation therapy: preliminary evaluation. Radiother Oncol. 1995;36:32–43
  31. Stroom JC, Korevaar GA, Koper PC, et al. Multiple two-dimensional versus three-dimensional PTV definition in treatment planning for conformal radiotherapy. Radiother Oncol. 1998;47:297–302
  32. Dobbs HJ, Parker RP. The respective roles of the simulator and computed tomography in radiotherapy planning: a review. Clin Radiol. 1984;35:433–439
  33. Lu R, Radke RJ, Happersett L, et al. Reduced-order parameter optimization for simplifying prostate IMRT planning. Phys Med Biol. 2007;52:849–870
  34. Chang BK, Timmerman RD. Stereotactic body radiation therapy: a comprehensive review. Am J Clin Oncol. 2007;30:637–644
  35. Pan T, Lee TY, Rietzel E, et al. 4D-CT imaging of a volume influenced by respiratory motion on multi-slice CT. Med Phys. 2004;31:333–340
  36. Rietzel E, Pan T, Chen GT. Four-dimensional computed tomography: image formation and clinical protocol. Med Phys. 2005;32:874–889
  37. Keall P, Vedam S, George R, et al. The clinical implementation of respiratory-gated intensity-modulated radiotherapy. Med Dosim. 2006;31:152–162
  38. Li XA, Keall PJ. Respiratory gating for radiation therapy is not ready for prime time. Med Phys. 2007;34:867–870
  39. Li G, Citrin D, Camphausen K, et al. Advances in 4D medical imaging and 4D radiation therapy. Technol Cancer Res Treat. 2008;7:67–82
  40. Erdi YE, Nehmeh SA, Pan T, et al. The CT motion quantitation of lung lesions and its impact on PET-measured SUVs. J Nucl Med. 2004;45:1287–1292
  41. Nehmeh SA, Erdi YE, Pan T, et al. Four-dimensional (4D) PET/CT imaging of the thorax. Med Phys. 2004;31:3179–3186
  42. Nehmeh SA, Erdi YE, Pan T, Yorke E, et al. Quantitation of respiratory motion during 4D-PET/CT acquisition. Med Phys. 2004;31:1333–1338
  43. Lamare F, Ledesma Carbayo MJ, Cresson T, et al. List-mode-based reconstruction for respiratory motion correction in PET using non-rigid body transformations. Phys Med Biol. 2007;52:5187–5204
  44. Li T, Thorndyke B, Schreibmann E, et al. Model-based image reconstruction for four-dimensional PET. Med Phys. 2006;33:1288–1298
  45. Nehmeh SA, Erdi YE. Respiratory motion in positron emission tomography/computed tomography: a review. Sem Nucl Med. 2008;38:167–176
  46. Dawood M, Buther F, Jiang X, et al. Respiratory motion correction in 3-D PET data with advanced optical flow algorithms. IEEE Trans Med Imaging. 2008;27:1164–1175
  47. Papathanassiou D, Becker S, Amir R, et al. Respiratory motion artefact in the liver dome on FDG PET/CT: comparison of attenuation correction with CT and a caesium external source. Eur J Nucl Med Mol Imaging. 2005;32:1422–1428
  48. Osman MM, Cohade C, Nakamoto Y, et al. Clinically significant inaccurate localization of lesions with PET/CT: frequency in 300 patients. J Nucl Med. 2003;44:240–243
  49. Pan T, Mawlawi O, Nehmeh SA, et al. Attenuation correction of PET images with respiration-averaged CT images in PET/CT. J Nucl Med. 2005;46:1481–1487
  50. Xing L, Thorndyke B, Schreibmann E, et al. Overview of image-guided radiation therapy. Med Dosim. 2006;31:91–112
  51. Shirato H, Shimizu S, Kitamura K, et al. Organ motion in image-guided radiotherapy: lessons from real-time tumor-tracking radiotherapy. Int J Clin Oncol. 2007;12:8–16
  52. Xing L, Siebers J, Keall P. Computational challenges for image-guided radiation therapy: framework and current research. Semin Rad Oncol. 2007;7:245–257
  53. Fenwick JD, Tome WA, Soisson ET, et al. Tomotherapy and other innovative IMRT delivery systems. Semin Radiat Oncol. 2006;16:199–208
  54. Mackie TR. History of tomotherapy. Phys Med Biol. 2006;51:R427–R453
  55. Otto K. Volumetric modulated arc therapy: IMRT in a single gantry arc. Med Phys. 2008;35:310–317
  56. Cozzi L, Dinshaw KA, Shrivastava SK, et al. A treatment planning study comparing volumetric arc modulation with RapidArc and fixed field IMRT for cervix uteri radiotherapy. Radiother Oncol. 2008;89:180–191
  57. Ling CC, Zhang P, Archambault Y, et al. Commissioning and quality assurance of RapidArc radiotherapy delivery system. Int J Radiat Oncol Biol Phys. 2008;72:575–581
  58. Brahme A. Recent advances in light ion radiation therapy. Int J Radiat Oncol Biol Phys. 2004;58:603–616
  59. Amaldi U. Future trends in cancer therapy with particle accelerators. Z Med Phys. 2004;14:7–16
  60. Brada M, Pijls-Johannesma M, De Ruysscher D. Proton therapy in clinical practice: current clinical evidence. J Clin Oncol. 2007;25:965–970
  61. Jakel O, Karger CP, Debus J. The future of heavy ion radiotherapy. Med Phys. 2008;35:5653–5663
  62. Yoneoka Y, Tsumanuma I, Fukuda M, et al. Cranial base chordoma–long term outcome and review of the literature. Acta Neurochir (Wien). 2008;150:773–778discussion 778
  63. Pommier P, Liebsch NJ, Deschler DG, et al. Proton beam radiation therapy for skull base adenoid cystic carcinoma. Arch Otolaryngol Head Neck Surg. 2006;132:1242–1249
  64. Delaney TF, Liebsch NJ, Pedlow FX, et al. Phase II study of high-dose photon/proton radiotherapy in the management of spine sarcomas. Int J Radiat Oncol Biol Phys. In press.
  65. Habrand JL, Schneider R, Alapetite C, et al. Proton therapy in pediatric skull base and cervical canal low-grade bone malignancies. Int J Radiat Oncol Biol Phys. 2008;71:672–675
  66. Rutz HP, Weber DC, Goitein G, et al. Postoperative spot-scanning proton radiation therapy for chordoma and chondrosarcoma in children and adolescents: initial experience at Paul Scherrer Institute. Int J Radiat Oncol Biol Phys. 2008;71:220–225
  67. Combs SE, Nikoghosyan A, Jaekel O, et al. Carbon ion radiotherapy for pediatric patients and young adults treated for tumors of the skull base. Cancer. 2009;115:1348–1355
  68. Bennett GW, Archambeau JO, Archambeau BE, et al. Visualization and transport of positron emission from proton activation in vivo. Science. 1978;200:1151–1153
  69. Pawelke J, Byars L, Enghardt W, et al. The investigation of different cameras for in-beam PET imaging. Phys Med Biol. 1996;41:279–296
  70. Crespo P, Shakirin G, Enghardt W. On the detector arrangement for in-beam PET for hadron therapy monitoring. Phys Med Biol. 2006;51:2143–2163
  71. Attanasi F, Belcari N, Del Guerra A, et al. Comparison of two dedicated ‘in beam’ PET systems via simultaneous imaging of (12)C-induced beta(+)-activity. Phys Med Biol. 2009;54:N29–N35
  72. Nassalski A, Kapusta M, Batsch T, et al. Comparative study of scintillators for PET/CT detectors. IEEE Trans Nucl Sci. 2007;54:3–10
  73. Parodi K, Paganetti H, Cascio E, et al. PET/CT imaging for treatment verification after proton therapy: a study with plastic phantoms and metallic implants. Med Phys. 2007;34:419–435
  74. Kirkby C, Stanescu T, Rathee S, et al. Patient dosimetry for hybrid MRI-radiotherapy systems. Med Phys. 2008;35:1019–1027
  75. Hasegawa BH, Gingold EL, Reilly SM, et al. Description of a simultaneous emission-transmission CT system. Proc SPIE. 1990;1231:50–60
  76. Beyer T, Townsend D, Brun T, et al. A combined PET/CT scanner for clinical oncology. J Nucl Med. 2000;41:1369–1379
  77. Townsend D, Kinahan P, Beyer T. Attenuation correction for a combined 3D PET/CT scanner. Phys Medica. 1996;12(Suppl 1):43–48
  78. Kluetz PG, Meltzer CC, Villemagne VL, et al. Combined PET/CT imaging in oncology. Impact on patient management. Clin Positron Imaging. 2000;3:223–230
  79. Muehllehner G, Karp JS. Positron emission tomography. Phys Med Biol. 2006;51:R117–R137
  80. Zaidi H. Recent developments and future trends in nuclear medicine instrumentation. Z Med Phys. 2006;16:5–17
  81. Thompson CJ. Instrumentation for positron emission mammography. PET Clin. 2006;1:33–38
  82. Weinberg IN. Applications for positron emission mammography. Phys Med. 2006;21(Suppl1):132–137
  83. Huber JS, Choong WS, Moses WW, et al. Initial results of a positron tomograph for prostate imaging. IEEE Trans Nucl Sci. 2006;53:2653–2659
  84. Surti S, Kuhn A, Werner ME, et al. Performance of Philips Gemini TF PET/CT scanner with special consideration for its time-of-flight imaging capabilities. J Nucl Med. 2007;48:471–480
  85. Karp JS, Surti S, Daube-Witherspoon ME, et al. Benefit of time-of-flight in PET: experimental and clinical results. J Nucl Med. 2008;49:462–470
  86. Brenner DJ, Hall EJ. Computed tomography-an increasing source of radiation exposure. N Engl J Med. 2007;357:2277–2784
  87. Mori S, Endo M, Tsunoo T, et al. Physical performance evaluation of a 256-slice CT-scanner for four-dimensional imaging. Med Phys. 2004;31:1348–1356
  88. Klingebiel R, Siebert E, Diekmann S, et al. 4-D Imaging in cerebrovascular disorders by using 320-slice CT: feasibility and preliminary clinical experience. Acad Radiol. 2009;16:123–129
  89. Kalender WA. X-ray computed tomography. Phys Med Biol. 2006;51:R29–R43
  90. Boone JM. Multidetector CT: opportunities, challenges, and concerns associated with scanners with 64 or more detector rows. Radiology. 2006;241:334–337
  91. Steinert HC, von Schulthess GK. Initial clinical experience using a new integrated in-line PET/CT system. Br J Radiol. 2002;73:S36–S38
  92. Zaidi H. Is radionuclide transmission scanning obsolete for dual-modality PET/CT systems?. Eur J Nucl Med Mol Imaging. 2007;34:815–818
  93. Alavi A, Mavi A, Basu S, Fischman A. Is PET-CT the only option?. Eur J Nuc Med Mol Imaging. 2007;34:819–821
  94. Gambhir S, Czernin J, Schwimmer J, et al. A tabulated summary of the FDG PET literature. J Nucl Med. 2001;45:1S–93S
  95. Lardinois D, Weder W, Hany TF, et al. Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography. N Engl J Med. 2003;348:2500–2507
  96. Bar-Shalom R, Yefemov N, Guralnik L, et al. Clinical performance of PET/CT in evaluation of cancer: additional value for diagnostic imaging and patient management. J Nucl Med. 2003;44:1200–1209
  97. Cohade C, Wahl RL. Applications of positron emission tomography/computed tomography image fusion in clinical positron emission tomography—clinical use, interpretation, methods, diagnostic improvements. Semin Nucl Med. 2003;33:228–237
  98. Cherry SR. Multimodality in vivo imaging systems: twice the power or double the trouble?. Annu Rev Biomed Eng. 2006;8:35–62
  99. Zaidi H, Mawlawi O. Simultaneous PET/MR will replace PET/CT as the molecular multimodality imaging platform of choice. Med Phys. 2007;34:1525–1528
  100. Pichler BJ, Wehrl HF, Kolb A, et al. Positron emission tomography/magnetic resonance imaging: the next generation of multimodality imaging?. Sem Nucl Med. 2008;38:199–208
  101. Schlemmer HP, Pichler BJ, Schmand M, et al. Simultaneous MR/PET imaging of the human brain: feasibility study. Radiology. 2008;248:1028–1035
  102. Zaidi H, Montandon M-L, Slosman DO. Magnetic resonance imaging-guided attenuation and scatter corrections in three-dimensional brain positron emission tomography. Med Phys. 2003;30:937–948
  103. Zaidi H. Is MRI-guided attenuation correction a viable option for dual-modality PET/MR imaging?. Radiology. 2007;244:639–642
  104. Hofmann M, Steinke F, Scheel V, et al. MRI-based attenuation correction for PET/MRI: a novel approach combining pattern recognition and Atlas registration. J Nucl Med. 2008;49:1875–1883
  105. Gaa J, Rummeny EJ, Seemann MD. Whole-body imaging with PET/MRI. Eur J Med Res. 2004;30:309–312
  106. Seemann MD. Whole-body PET/MRI: the future in oncological imaging. Technol Cancer Res Treat. 2005;4:577–582
  107. Schlemmer HP, Pichler BJ, Krieg R, et al. An integrated MR/PET system: prospective applications. Abdom Imaging. In press.
  108. Hicks RJ, Lau EW. PET/MRI: a different spin from under the rim. Eur J Nucl Med Mol Imaging. 2009;36:10–14
  109. Payne GS, Leach MO. Applications of magnetic resonance spectroscopy in radiotherapy treatment planning. Br J Radiol. 2006;79(Spec No 1):S16–S26
  110. Torigian DA, Huang SS, Houseni M, et al. Functional imaging of cancer with emphasis on molecular techniques. CA Cancer J Clin. 2007;57:206–224
  111. Schoder H, Ong SC. Fundamentals of molecular imaging: rationale and applications with relevance for radiation oncology. Semin Nucl Med. 2008;38:119–128
  112. Kumar R, Dhanpathi H, Basu S, et al. Oncologic PET tracers beyond [(18)F]FDG and the novel quantitative approaches in PET imaging. Q J Nucl Med Mol Imaging. 2008;52:50–65
  113. Fowler JS, Ding YS, Volkow ND. Radiotracers for positron emission tomography imaging. Semin Nucl Med. 2003;33:14–27
  114. Weber WA, Figlin R. Monitoring cancer treatment with PET/CT: does it make a difference?. J Nucl Med. 2007;48:36S–44S
  115. Evans SM, Fraker D, Hahn SM, et al. EF5 binding and clinical outcome in human soft tissue sarcomas. Int J Radiat Oncol Biol Phys. 2006;64:922–927
  116. Grosu AL, Souvatzoglou M, Roper B, et al. Hypoxia imaging with FAZA-PET and theoretical considerations with regard to dose painting for individualization of radiotherapy in patients with head and neck cancer. Int J Radiat Oncol Biol Phys. 2007;69:541–551
  117. Wong TZ, Lacy JL, Petry NA, et al. PET of hypoxia and perfusion with 62Cu-ATSM and 62Cu-PTSM using a 62Zn/62Cu generator. AJR Am J Roentgenol. 2008;190:427–432
  118. Nehmeh SA, Lee NY, Schroder H, et al. Reproducibility of intratumor distribution of (18)F-fluoromisonidazole in head and neck cancer. Int J Radiat Oncol Biol Phys. 2008;70:235–242
  119. Rajendran JG, Hendrickson KR, Spence AM, et al. Hypoxia imaging-directed radiation treatment planning. Eur J Nucl Med Mol Imaging. 2006;33(Suppl 1):44–53
  120. Mankoff D, Shields A, Krohn K. PET imaging of cellular proliferation. Radiol Clin North Am. 2005;43:153–167
  121. Fischman A. Role of [18F]-dopa-PET imaging in assessing movement disorders. Radiol Clin North Am. 2005;43:93–106
  122. Jager PL, Chirakal R, Marriott CJ, et al. 6-L-18F-Fluorodihydroxyphenylalanine PET in neuroendocrine tumors: Basic aspects and emerging clinical applications. J Nucl Med. 2008;49:573–586
  123. Nanni C, Fanti S, Rubello D. 18F-DOPA PET and PET/CT. J Nucl Med. 2007;48:1577–1579
  124. Belvisi L, Bernardi A, Colombo M, et al. Targeting integrins: insights into structure and activity of cyclic RGD pentapeptide mimics containing azabicycloalkane amino acids. Bioorg Med Chem. 2006;14:169–180
  125. Beer AJ, Grosu AL, Carlsen J, et al. [18F]Galacto-RGD positron emission tomography for imaging of {alpha}v{beta}3 expression on the neovasculature in patients with squamous cell carcinoma of the head and neck. Clin Cancer Res. 2007;13:6610–6616
  126. Couturier O, Luxen A, Chatal JF, et al. Fluorinated tracers for imaging cancer with positron emission tomography. Eur J Nucl Med Mol Imaging. 2004;31:1182–1206
  127. Blankenberg F, Katsikis P, Tait J, et al. In vivo detection and imaging of phosphatidylserine expression during programmed cell death. Proc Natl Acad Sci U S A. 1998;95:6349–6354
  128. Rahn AN, Baum RP, Adamietz IA, et al. (Value of 18F fluorodeoxyglucose positron emission tomography in radiotherapy planning of head-neck tumors). Strahlenther Onkol. 1998;174:358–364
  129. Gross MW, Weber WA, Feldmann HJ, et al. The value of F-18-fluorodeoxyglucose PET for the 3-D radiation treatment planning of malignant gliomas. Int J Radiat Oncol Biol Phys. 1998;41:989–995
  130. Kiffer JD, Berlangieri SU, Scott AM, et al. The contribution of 18F-fluoro-2-deoxy-glucose positron emission tomographic imaging to radiotherapy planning in lung cancer. Lung Cancer. 1998;19:167–177
  131. Scarfone C, Jaszczak RJ, Gilland DR, et al. Quantitative pulmonary single photon emission computed tomography for radiotherapy applications. Med Phys. 1999;26:1579–1588
  132. Munley MT, Marks LB, Scarfone C, et al. Multimodality nuclear medicine imaging in three-dimensional radiation treatment planning for lung cancer: challenges and prospects. Lung Cancer. 1999;23:105–114
  133. Nestle U, Walter K, Schmidt S, et al. 18F-deoxyglucose positron emission tomography (FDG-PET) for the planning of radiotherapy in lung cancer: high impact in patients with atelectasis. Int J Radiat Oncol Biol Phys. 1999;44:593–597
  134. Vanuytsel LJ, Vansteenkiste JF, Stroobants SG, et al. The impact of 18F-fluoro-2-deoxy–glucose positron emission tomography (FDG-PET) lymph node staging on the radiation treatment volumes in patients with non-small cell lung cancer. Radiother Oncol. 2000;55:317–324
  135. Levivier M, Wikier D, Goldman S, et al. Integration of the metabolic data of positron emission tomography in the dosimetry planning of radiosurgery with the gamma knife: early experience with brain tumors. Technical note. J Neurosurg. 2000;93(Suppl 3):233–238
  136. Ling C, Humm J, Larson S, et al. Towards multidimensional radiotherapy (MD-CRT): biological imaging and biological conformality. Int J Radiat Oncol Biol Phys. 2000;47:551–560
  137. Scarfone C, Lavely WC, Cmelak AJ, et al. Prospective feasibility trial of radiotherapy target definition for head and neck cancer using 3-dimensional PET and CT imaging. J Nucl Med. 2004;45:543–552
  138. Paulino AC, Thorstad WL, Fox T. Role of fusion in radiotherapy treatment planning. Semin Nucl Med. 2003;33:238–243
  139. Yap JT, Carney JP, Hall NC, Townsend DW. Image-guided cancer therapy using PET/CT. Cancer J. 2004;10:221–233
  140. Brunetti J, Caggiano A, Rosenbluth B, et al. Technical aspects of positron emission tomography/computed tomography fusion planning. Sem Nucl Med. 2008;38:129–136
  141. Greco C, Rosenzweig K, Cascini GL, et al. Current status of PET/CT for tumour volume definition in radiotherapy treatment planning for non-small cell lung cancer (NSCLC). Lung Cancer. 2007;57:125–134
  142. Stroom J, Blaauwgeers H, van Baardwijk A, et al. Feasibility of pathology-correlated lung imaging for accurate target definition of lung tumors. Int J Radiat Oncol Biol Phys. 2007;69:267–275
  143. Mah K, Caldwell CB, Ung YC, et al. The impact of (18)FDG-PET on target and critical organs in CT-based treatment planning of patients with poorly defined non-small-cell lung carcinoma: a prospective study. Int J Radiat Oncol Biol Phys. 2002;52:339–350
  144. Caldwell CB, Mah K, Skinner M, et al. Can PET provide the 3D extent of tumor motion for individualized internal target volumes? A phantom study of the limitations of CT and the promise of PET. Int J Radiat Oncol Biol Phys. 2003;55:1381–1393
  145. Bradley J, Thorstad WL, Mutic S, et al. Impact of FDG-PET on radiation therapy volume delineation in non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2004;59:78–86
  146. Nestle U, Kremp S, Grosu AL. Practical integration of [18F]-FDG-PET and PET-CT in the planning of radiotherapy for non-small cell lung cancer (NSCLC): the technical basis, ICRU-target volumes, problems, perspectives. Radiother Oncol. 2006;81:209–225
  147. Levy RP. PET-CT: evolving role in 3-D radiation therapy. Technol Cancer Res Treat. 2006;5:101–107
  148. Grosu AL, Weber WA, Astner ST, et al. 11C-methionine PET improves the target volume delineation of meningiomas treated with stereotactic fractionated radiotherapy. Int J Radiat Oncol Biol Phys. 2006;66:339–344
  149. Macapinlac HA. Clinical applications of positron emission tomography/computed tomography treatment planning. Semin Nucl Med. 2008;38:137–140
  150. Dizendorf EV, Baumert BG, von Schulthess GK, et al. Impact of whole-body 18F-FDG PET on staging and managing patients for radiation therapy. J Nucl Med. 2003;44:24–29
  151. Czernin J, Phelps ME. Positron emission tomography scanning: current and future applications. Annu Rev Med. 2002;53:89–112
  152. Lammering G, De Haas D, De Ruysscher D, et al. First report on the use of a dedicated combined CT-PET simulator in rectal cancer patients [abstract]. Radiother Oncol 2004; ESTRO 23:S441.
  153. Weder W, Schmid RA, Bruchhaus H, et al. C. Detection of extrathoracic metastases by positron emission tomography in lung cancer. Ann Thorac Surg. 1998;66:886–892discussion 892–893
  154. Kalff V, Hicks RJ, MacManus MP, et al. Clinical impact of (18)F fluorodeoxyglucose positron emission tomography in patients with non-small-cell lung cancer: a prospective study. J Clin Oncol. 2001;19:111–118
  155. van Baardwijk A, Bosmans G, Boersma L, et al. PET-CT-based auto-contouring in non-small-cell lung cancer correlates with pathology and reduces interobserver variability in the delineation of the primary tumor and involved nodal volumes. Int J Radiat Oncol Biol Phys. 2007;68:771–778
  156. Caldwell CB, Mah K, Ung YC, et al. Observer variation in contouring gross tumor volume in patients with poorly defined non-small-cell lung tumors on CT: the impact of 18FDG-hybrid PET fusion. Int J Radiat Oncol Biol Phys. 2001;51:923–931
  157. Fox JL, Rengan R, O'Meara W, et al. Does registration of PET and planning CT images decrease interobserver and intraobserver variation in delineating tumor volumes for non-small-cell lung cancer?. Int J Radiat Oncol Biol Phys. 2005;62:70–75
  158. Ciernik IF, Dizendorf E, Baumert BG, et al. Radiation treatment planning with an integrated positron emission and computer tomography (PET/CT): a feasibility study. Int J Radiat Oncol Biol Phys. 2003;57:853–863
  159. Deniaud-Alexandre E, Touboul E, Lerouge D, et al. Impact of computed tomography and 18F-deoxyglucose coincidence detection emission tomography image fusion for optimization of conformal radiotherapy in non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2005;63:1432–1441
  160. Ashamalla H, Rafla S, Parikh K, et al. The contribution of integrated PET/CT to the evolving definition of treatment volumes in radiation treatment planning in lung cancer. Int J Radiat Oncol Biol Phys. 2005;63:1016–1023
  161. Hong R, Halama J, Bova D, et al. Correlation of PET standard uptake value and CT window-level thresholds for target delineation in CT-based radiation treatment planning. Int J Radiat Oncol Biol Phys. 2007;67:720–726
  162. Paulino AC, Koshy M, Howell R, et al. Comparison of CT- and FDG-PET-defined gross tumor volume in intensity-modulated radiotherapy for head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2005;61:1385–1392
  163. Schwartz DL, Ford EC, Rajendran J, et al. FDG-PET/CT-guided intensity modulated head and neck radiotherapy: a pilot investigation. Head Neck. 2005;27:478–487
  164. Geets X, Daisne JF, Tomsej M, et al. Impact of the type of imaging modality on target volumes delineation and dose distribution in pharyngo-laryngeal squamous cell carcinoma: comparison between pre- and per-treatment studies. Radiother Oncol. 2006;78:291–297
  165. Daisne JF, Duprez T, Weynand B, et al. Tumor volume in pharyngolaryngeal squamous cell carcinoma: comparison at CT, MR imaging, and FDG PET and validation with surgical specimen. Radiology. 2004;233:93–100
  166. Burri RJ, Rangaswamy B, Kostakoglu L, et al. Correlation of positron emission tomography standard uptake value and pathologic specimen size in cancer of the head and neck. Int J Radiat Oncol Biol Phys. 2008;71:682–628
  167. van Baardwijk A, Baumert BG, Bosmans G, et al. The current status of FDG-PET in tumour volume definition in radiotherapy treatment planning. Cancer Treat Rev. 2006;32:245–260
  168. Vernon MR, Maheshwari M, Schultz CJ, et al. Clinical outcomes of patients receiving integrated PET/CT-guided radiotherapy for head and neck carcinoma. Int J Radiat Oncol Biol Phys. 2008;70:678–684
  169. Weng E, Tran L, Rege S, et al. Accuracy and clinical impact of mediastinal lymph node staging with FDG-PET imaging in potentially resectable lung cancer. Am J Clin Oncol. 2000;23:47–52
  170. De Ruysscher D, Wanders S, Minken A, et al. Effects of radiotherapy planning with a dedicated combined PET-CT-simulator of patients with non-small cell lung cancer on dose limiting normal tissues and radiation dose-escalation: a planning study. Radiother Oncol. 2005;77:5–10
  171. Messa C, Ceresoli GL, Rizzo G, et al. Feasibility of [18F]FDG-PET and coregistered CT on clinical target volume definition of advanced non-small cell lung cancer. Q J Nucl Med Mol Imaging. 2005;49:259–266
  172. Luketich JD, Friedman DM, Meltzer CC, et al. The role of positron emission tomography in evaluating mediastinal lymph node metastases in non-small-cell lung cancer. Clin Lung Cancer. 2001;2:229–233
  173. Everitt S, Schneider-Kolsky M, Yuen K, et al. Dose escalation of radical radiation therapy in non-small-cell lung cancer using positron emission tomography/computed tomography-defined target volumes: are class solutions obsolete?. J Med Imaging Radiat Oncol. 2008;52:168–177
  174. Klopp AH, Chang JY, Tucker SL, et al. Intrathoracic patterns of failure for non-small-cell lung cancer with positron-emission tomography/computed tomography-defined target delineation. Int J Radiat Oncol Biol Phys. 2007;69:1409–1416
  175. De Ruysscher D, Wanders S, van Haren E, et al. Selective mediastinal node irradiation based on FDG-PET scan data in patients with non-small-cell lung cancer: a prospective clinical study. Int J Radiat Oncol Biol Phys. 2005;62:988–994
  176. Neicu T, Berbeco R, Wolfgang J, et al. Synchronized moving aperture radiation therapy (SMART): improvement of breathing pattern reproducibility using respiratory coaching. Phys Med Biol. 2006;51:617–636
  177. Yaremko B, Riauka T, Robinson D, et al. Thresholding in PET images of static and moving targets. Phys Med Biol. 2005;50:5969–5982
  178. Nestle U, Kremp S, Schaefer-Schuler A, et al. Comparison of different methods for delineation of 18F-FDG PET-positive tissue for target volume definition in radiotherapy of patients with non-Small cell lung cancer. J Nucl Med. 2005;6:1342–1348
  179. Belhassen S, Llina Fuentes CS, Dekker A, et al. Comparative methods for 18F-FDG PET-based delineation of target volumes in non-small-cell lung cancer [abstract]. J Nucl Med. 2009;50:In press
  180. van Westreenen HL, Westerterp M, Bossuyt PMM, et al. Systematic review of the staging performance of 18F-Fluorodeoxyglucose positron emission tomography in esophageal cancer. J Clin Oncol. 2004;22:3805–3812
  181. Vrieze O, Haustermans K, De Wever W, et al. Is there a role for FGD-PET in radiotherapy planning in esophageal carcinoma?. Radiother Oncol. 2004;73:269–275
  182. Vinjamuri S, Ray S. Added value of PET and PET-CT in oesophageal cancer: a review of current practice. Nucl Med Commun. 2008;29:4–10
  183. van Vliet EP, Heijenbrok-Kal MH, Hunink MG, et al. Staging investigations for oesophageal cancer: a meta-analysis. Br J Cancer. 2008;98:547–557
  184. Bruzzi JF, Munden RF, Truong MT, Marom EM, Sabloff BS, Gladish GW, et al. PET/CT of esophageal cancer: its role in clinical management. Radiographics. 2007;27:1635–1652
  185. Narayan K, Hicks RJ, Jobling T, et al. A comparison of MRI and PET scanning in surgically staged loco-regionally advanced cervical cancer: potential impact on treatment. Int J Gynecol Cancer. 2001;11:263–271
  186. Khan N, Oriuchi N, Yoshizaki A, et al. Diagnostic accuracy of FDG PET imaging for the detection of recurrent or metastatic gynecologic cancer. Ann Nucl Med. 2005;19:137–145
  187. Grisaru D, Almog B, Levine C, et al. The diagnostic accuracy of 18F-fluorodeoxyglucose PET/CT in patients with gynecological malignancies. Gynecol Oncol. 2004;94:680–684
  188. Nakamoto Y, Saga T, Fujii S. Positron emission tomography application for gynecologic tumors. Int J Gynecol Cancer. 2005;15:701–709
  189. Esthappan J, Mutic S, Malyapa RS, et al. Treatment planning guidelines regarding the use of CT/PET-guided IMRT for cervical carcinoma with positive paraaortic lymph nodes. Int J Radiat Oncol Biol Phys. 2004;58:1289–1297
  190. Mutic S, Grigsby PW, Low DA, et al. PET-guided three-dimensional treatment planning of intracavitary gynecologic implants. Int J Radiat Oncol Biol Phys. 2002;52:1104–1110
  191. Mutic S, Malyapa RS, Grigsby PW, et al. PET-guided IMRT for cervical carcinoma with positive para-aortic lymph nodes—a dose-escalation treatment planning study. Int J Radiat Oncol Biol Phys. 2003;55:28–35
  192. Kantorova I, Lipska L, Belohlavek O, et al. Routine (18)F-FDG PET preoperative staging of colorectal cancer: comparison with conventional staging and its impact on treatment decision making. J Nucl Med. 2003;44:1784–1788
  193. Anderson C, Koshy M, Staley C, et al. PET-CT fusion in radiation management of patients with anorectal tumors. Int J Radiat Oncol Biol Phys. 2007;69:155–162
  194. Podoloff DA, Macapinlac HA. PET and PET/CT in management of the lymphomas. Radiol Clin North Am. 2007;45:689–696
  195. Juweid ME, Stroobants S, Hoekstra OS, et al. Use of positron emission tomography for response assessment of lymphoma: consensus of the imaging subcommittee of International harmonization project in lymphoma. J Clin Oncol. 2007;25:571–578
  196. Lee YK, Cook G, Flower MA, et al. Addition of 18F-FDG-PET scans to radiotherapy planning of thoracic lymphoma. Radiother Oncol. 2004;73:277–283
  197. Girinsky T, Ghalibafian M, Bonniaud G, et al. Is FDG-PET scan in patients with early stage Hodgkin lymphoma of any value in the implementation of the involved-node radiotherapy concept and dose painting?. Radiother Oncol. 2007;85:178–186
  198. Hutchings M, Loft A, Hansen M, et al. Clinical impact of FDG-PET/CT in the planning of radiotherapy for early-stage Hodgkin lymphoma. Eur J Haematol. 2007;78:206–212
  199. Veronesi U, De Cicco C, Galimberti V, et al. A comparative study on the value of FDG-PET and sentinel node biopsy to identify occult axillary metastases. Ann Oncol. 2007;18:473–478
  200. Barranger E, Grahek D, Antoine M, et al. Evaluation of fluorodeoxyglucose positron emission tomography in the detection of axillary lymph node metastases in patients with early-stage breast cancer. Ann Surg Oncol. 2003;10:622–627
  201. Zornoza G, Garcia-Velloso MJ, Sola J, et al. 18F-FDG PET complemented with sentinel lymph node biopsy in the detection of axillary involvement in breast cancer. Eur J Surg Oncol. 2004;30:15–19
  202. Lovrics PJ, Chen V, Coates G, et al. A prospective evaluation of positron emission tomography scanning, sentinel lymph node biopsy, and standard axillary dissection for axillary staging in patients with early stage breast cancer. Ann Surg Oncol. 2004;11:846–853
  203. Cardillo A, De Cicco C, Paganelli G, et al. Role of fluorodeoxyglucose positron emission tomography in the staging of patients with breast cancer candidated to surgery. Ann Oncol. 2007;18:394–395
  204. Gil-Rendo A, Zornoza G, Garcia-Velloso MJ, et al. Fluorodeoxyglucose positron emission tomography with sentinel lymph node biopsy for evaluation of axillary involvement in breast cancer. Br J Surg. 2006;93:707–712
  205. Mavi A, Urhan M, Yu JQ, et al. Dual time point 18F-FDG PET imaging detects breast cancer with high sensitivity and correlates well with histologic subtypes. J Nucl Med. 2006;47:1440–1446
  206. Heusner TA, Freudenberg LS, Kuehl H, et al. Whole-body PET/CT-mammography for staging breast cancer: initial results. Br J Radiol. 2008;81:743–748
  207. Heusner TA, Kuemmel S, Umutlu L, et al. Breast cancer staging in a single session: whole-body PET/CT mammography. J Nucl Med. 2008;49:1215–1222
  208. Bral S, Vinh-Hung V, Everaert H, et al. The use of molecular imaging to evaluate radiation fields in the adjuvant setting of breast cancer: a feasibility study. Strahlenther Onkol. 2008;184:100–104
  209. Doshi NK, Silverman RW, Shao Y, et al. maxPET, a dedicated mammary and axillary region PET imaging system for breast cancer. IEEE Trans Nucl Sci. 2001;48:811–815
  210. Levin CS, Foudray AM, Habte F. Impact of high energy resolution detectors on the performance of a PET system dedicated to breast cancer imaging. Phys Med. 2006;21(Suppl 1):28–34
  211. Abreu MC, et al. Clear-PEM: a PET imaging system dedicated to breast cancer diagnostics. Nucl Instr Meth A. 2007;571:81–84
  212. Surti S, Karp JS. Design considerations for a limited angle, dedicated breast, TOF PET scanner. Phys Med Biol. 2008;53:2911–2921
  213. Murthy K, Aznar M, Thompson CJ, et al. Results of preliminary clinical trials of the positron emission mammography system PEM-I: a dedicated breast imaging system producing glucose metabolic images using FDG. J Nucl Med. 2000;41:1851–1858
  214. Rosen EL, Turkington TG, Soo MS, et al. Detection of primary breast carcinoma with a dedicated, large-field-of-view FDG PET mammography device: initial experience. Radiology. 2005;234:527–534
  215. Raylman RR, Majewski S, Smith MF, et al. The positron emission mammography/tomography breast imaging and biopsy system (PEM/PET): design, construction and phantom-based measurements. Phys Med Biol. 2008;53:637–653
  216. Zangheri B, Messa C, Picchio M, et al. PET/CT and breast cancer. Eur J Nuc Med Mol Imaging. 2004;31:S135–S142
  217. Lindfors KK, Boone JM, Nelson TR, et al. Dedicated breast CT: initial clinical experience. Radiology. 2008;246:725–733
  218. Liang H, Yang Y, Yang K, et al. A microPET/CT system for in vivo small animal imaging. Phys Med Biol. 2007;52:3881–3894
  219. Grosu AL, Piert M, Weber WA, et al. Positron emission tomography for radiation treatment planning. Strahlenther Onkol. 2005;181:483–499
  220. Koch CJ, Evans SM. Non-invasive PET and SPECT imaging of tissue hypoxia using isotopically labeled 2-nitroimidazoles. Adv Exp Med Biol. 2003;510:285–292
  221. Beck R, Roper B, Carlsen JM, et al. Pretreatment 18F-FAZA PET predicts success of hypoxia-directed radiochemotherapy using tirapazamine. J Nucl Med. 2007;48:973–980
  222. Sorger D, Patt M, Kumar P, et al. [18F]Fluoroazomycinarabinofuranoside (18FAZA) and [18F]Fluoromisonidazole (18FMISO): a comparative study of their selective uptake in hypoxic cells and PET imaging in experimental rat tumors. Nucl Med Biol. 2003;30:317–326
  223. Tanaka T, Furukawa T, Fujieda S, et al. Double-tracer autoradiography with Cu-ATSM/FDG and immunohistochemical interpretation in four different mouse implanted tumor models. Nucl Med Biol. 2006;33:743–750
  224. Rischin D, Hicks RJ, Fisher R, et al. Prognostic significance of [18F]-misonidazole positron emission tomography-detected tumor hypoxia in patients with advanced head and neck cancer randomly assigned to chemoradiation with or without tirapazamine: a substudy of Trans-Tasman Radiation Oncology Group Study 98.02. J Clin Oncol. 2006;24:2098–2104
  225. Thorwarth D, Eschmann SM, Scheiderbauer J, et al. Kinetic analysis of dynamic 18F-fluoromisonidazole PET correlates with radiation treatment outcome in head-and-neck cancer. BMC Cancer. 2005;5:152
  226. Lee NY, Mechalakos JG, Nehmeh S, et al. Fluorine-18-labeled fluoromisonidazole positron emission and computed tomography-guided intensity-modulated radiotherapy for head and neck cancer: a feasibility study. Int J Radiat Oncol Biol Phys. 2008;70:2–13
  227. Lin Z, Mechalakos J, Nehmeh S, et al. The influence of changes in tumor hypoxia on dose-painting treatment plans based on (18)F-FMISO positron emission tomography. Int J Radiat Oncol Biol Phys. 2008;70:1219–1228
  228. Eschmann SM, Paulsen F, Reimold M, et al. Prognostic impact of hypoxia imaging with 18F-misonidazole PET in non-small cell lung cancer and head and neck cancer before radiotherapy. J Nucl Med. 2005;46:253–260
  229. Lawrentschuk N, Poon AM, Foo SS, et al. Assessing regional hypoxia in human renal tumours using 18F-fluoromisonidazole positron emission tomography. BJU Int. 2005;96:540–546
  230. Rajendran JG, Wilson DC, Conrad EU, et al. [(18)F]FMISO and [(18)F]FDG PET imaging in soft tissue sarcomas: correlation of hypoxia, metabolism and VEGF expression. Eur J Nucl Med Mol Imaging. 2003;30:695–704
  231. Eschmann SM, Paulsen F, Bedeshem C, et al. Hypoxia-imaging with (18)F-Misonidazole and PET: changes of kinetics during radiotherapy of head-and-neck cancer. Radiother Oncol. 2007;83:406–410
  232. Dolbier WR, Li AR, Koch CJ, et al. [18F]-EF5, a marker for PET detection of hypoxia: synthesis of precursor and a new fluorination procedure. Appl Radiat Isot. 2001;54:73–80
  233. Komar G, Seppanen M, Eskola O, et al. 18F-EF5: a new PET tracer for imaging hypoxia in head and neck cancer. J Nucl Med. 2008;49:1944–1951
  234. Evans S, Hahn S, Judy K, et al. 18F EF5 PET imaging with imunohistochemical validation in patients with brain lesions [abstract]. Int J Rad Oncol Biol Phys. 2006;66:S248
  235. Reinhardt MJ, Kubota K, Yamada S, et al. Assessment of cancer recurrence in residual tumors after fractionated radiotherapy: a comparison of fluorodeoxyglucose. L-methionine and thymidine. J Nucl Med. 1997;38:280–287
  236. Grosu AL, Weber WA, Riedel E, et al. L-(methyl-11C) methionine positron emission tomography for target delineation in resected high-grade gliomas before radiotherapy. Int J Radiat Oncol Biol Phys. 2005;63:64–74
  237. Terakawa Y, Tsuyuguchi N, Iwai Y, et al. Diagnostic accuracy of 11C-methionine PET for differentiation of recurrent brain tumors from radiation necrosis after radiotherapy. J Nucl Med. 2008;49:694–699
  238. Singhal T, Narayanan TK, Jain V, et al. 11C-L-methionine positron emission tomography in the clinical management of cerebral gliomas. Mol Imaging Biol. 2008;10:1–18
  239. Nariai T, Tanaka Y, Wakimoto H, et al. Usefulness of L-[methyl-11C] methionine-positron emission tomography as a biological monitoring tool in the treatment of glioma. J Neurosurg. 2005;103:498–507
  240. Rachinger W, Goetz C, Popperl G, et al. Positron emission tomography with O-(2-[18F]fluoroethyl)-l-tyrosine versus magnetic resonance imaging in the diagnosis of recurrent gliomas. Neurosurgery. 2005;57:505–511
  241. Astner ST, Dobrei-Ciuchendea M, Essler M, et al. Effect of (11)C-methionine-positron emission tomography on gross tumor volume delineation in stereotactic radiotherapy of skull base meningiomas. Int J Radiat Oncol Biol Phys. 2008;72:1161–1167
  242. Grosu AL, Lachner R, Wiedenmann N, et al. Validation of a method for automatic image fusion (BrainLAB System) of CT data and 11C-methionine-PET data for stereotactic radiotherapy using a LINAC: first clinical experience. Int J Radiat Oncol Biol Phys. 2003;56:1450–1463
  243. Grosu AL, Weber WA, Franz M, et al. Reirradiation of recurrent high-grade gliomas using amino acid PET (SPECT)/CT/MRI image fusion to determine gross tumor volume for stereotactic fractionated radiotherapy. Int J Radiat Oncol Biol Phys. 2005;63:511–519
  244. Plotkin M, Gneveckow U, Meier-Hauff K, et al. 18F-FET PET for planning of thermotherapy using magnetic nanoparticles in recurrent glioblastoma. Int J Hyperthermia. 2006;22:319–325
  245. Levivier M, Massager N, Wikler D, et al. Integration of functional imaging in radiosurgery: the example of PET scan. Prog Neurol Surg. 2007;20:68–81
  246. Mahasittiwat P, Mizoe JE, Hasegawa A, et al. l-[METHYL-(11)C] methionine positron emission tomography for target delineation in malignant gliomas: impact on results of carbon ion radiotherapy. Int J Radiat Oncol Biol Phys. 2008;70:515–522
  247. Miwa K, Matsuo M, Shinoda J, et al. Simultaneous integrated boost technique by helical tomotherapy for the treatment of glioblastoma multiforme with (11)C-methionine PET: report of three cases. J Neurooncol. 2008;87:333–339
  248. Tang BN, Levivier M, Heureux M, et al. 11C-methionine PET for the diagnosis and management of recurrent pituitary adenomas. Eur J Nucl Med Mol Imaging. 2006;33:169–178
  249. Vees H, Senthamizhchelvan S, Miralbell R, et al. Assessment of various strategies for 18F-FET PET-guided delineation of target volumes in high-grade glioma patients. Eur J Nucl Med Mol Imaging. 2009;36:182–193
  250. Weber DC, Zilli T, Buchegger F, et al. [(18)F]Fluoroethyltyrosine- positron emission tomography-guided radiotherapy for high-grade glioma. Radiat Oncol. 2008;3:44
  251. de Jong IJ, Pruim J, Elsinga PH, et al. 11C-choline positron emission tomography for the evaluation after treatment of localized prostate cancer. Eur Urol. 2003;44:32–38discussion 38–39
  252. Heinisch M, Dirisamer A, Loidl W, et al. Positron emission tomography/computed tomography with F-18-fluorocholine for restaging of prostate cancer patients: meaningful at PSA < 5 ng/ml?. Mol Imaging Biol. 2006;8:43–48
  253. Picchio M, Messa C, Landoni C, et al. Value of [11C]choline-positron emission tomography for re-staging prostate cancer: a comparison with [18F]fluorodeoxyglucose-positron emission tomography. J Urol. 2003;169:1337–1340
  254. Reske SN, Blumstein NM, Glatting G. [(11)C]choline PET/CT imaging in occult local relapse of prostate cancer after radical prostatectomy. Eur J Nucl Med Mol Imaging. 2008;35:9–17
  255. Vees H, Buchegger F, Albrecht S, et al. 18F-choline and/or 11C-acetate positron emission tomography: detection of residual or progressive subclinical disease at very low prostate-specific antigen values (<1 ng/mL) after radical prostatectomy. BJU Int. 2007;99:1415–1420
  256. Steiner C, Vees H, Zaidi H, et al. Three-phase 18F-fluorocholine PET/CT in the evaluation of prostate cancer recurrence. Nuklearmedizin. 2009;48:1–9
  257. Ciernik IF, Brown DW, Schmid D, et al. 3D-segmentation of the 18F-choline PET signal for target volume definition in radiation therapy of the prostate. Technol Cancer Res Treat. 2007;6:23–30
  258. Picozzi P, Rizzo G, Landoni C, et al. A simplified method to integrate metabolic images in stereotactic procedures using a PET/CT scanner. Stereotact Funct Neurosurg. 2005;83:208–212
  259. Rickhey M, Bogner L. Application of the inverse Monte Carlo treatment planning system IKO for an inhomogeneous dose prescription in the sense of dose painting. Z Med Phys. 2006;16:307–312
  260. Sugiyama M, Sakahara H, Sato K, et al. Evaluation of 3'-deoxy-3'-18F-fluorothymidine for monitoring tumor response to radiotherapy and photodynamic therapy in mice. J Nucl Med. 2004;45:1754–1758
  261. Gabriel M, Decristoforo C, Kendler D, et al. 68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT. J Nucl Med. 2007;48:508–518
  262. Milker-Zabel S, Zabel-du Bois A, Henze M, et al. Improved target volume definition for fractionated stereotactic radiotherapy in patients with intracranial meningiomas by correlation of CT, MRI, and [68Ga]-DOTATOC-PET. Int J Radiat Oncol Biol Phys. 2006;65:222–227
  263. Austin-Seymour M, Chen GT, Rosenman J, et al. Tumor and target delineation: current research and future challenges. Int J Radiat Oncol Biol Phys. 1995;33:1041–1052
  264. Van Hoe L, Haven F, Bellon E, et al. Factors influencing the accuracy of volume measurements in spiral CT: a phantom study. J Comput Assist Tomogr. 1997;21:332–338
  265. Bowden P, Fisher R, Mac Manus M, et al. Measurement of lung tumor volumes using three-dimensional computer planning software. Int J Radiat Oncol Biol Phys. 2002;53:566–573
  266. Senan S, Chapet O, Lagerwaard FJ, et al. Defining target volumes for non-small cell lung carcinoma. Semin Radiat Oncol. 2004;14:308–314
  267. Chaney E, Ibbott G, Hendee WR. Methods for image segmentation should be standardized and calibrated. Med Phys. 2005;32:3507–3510
  268. Evans PM. Anatomical imaging for radiotherapy. Phys Med Biol. 2008;53:R151–R191
  269. Rasch C, Barillot I, Remeijer P, et al. Definition of the prostate in CT and MRI: a multi-observer study. Int J Rad Oncol Biol Phys. 1999;43:57–66
  270. Khoo VS, Adams EJ, Saran F, et al. A comparison of clinical target volumes determined by CT and MRI for the radiotherapy planning of base of skull meningiomas. Int J Rad Oncol Biol Phys. 2000;46:1309–1317
  271. Lee YK, Bollet M, Charles-Edwards G, et al. Radiotherapy treatment planning of prostate cancer using magnetic resonance imaging alone. Radiother Oncol. 2003;66:203–216
  272. Chen L, Price J, Robert A, et al. MRI-based treatment planning for radiotherapy: Dosimetric verification for prostate IMRT. Int J Rad Oncol Biol Phys. 2004;60:636–647
  273. Schinagl DA, Kaanders JH, Oyen WJ. From anatomical to biological target volumes: the role of PET in radiation treatment planning. Cancer Imaging. 2006;6:S107–S116
  274. Ashamalla H, Guirgius A, Bieniek E, et al. The impact of positron emission tomography/computed tomography in edge delineation of gross tumor volume for head and neck cancers. Int J Radiat Oncol Biol Phys. 2007;68:388–395
  275. Newbold K, Partridge M, Cook G, et al. Advanced imaging applied to radiotherapy planning in head and neck cancer: a clinical review. Br J Radiol. 2006;79:554–561
  276. Lavrenkov K, Partridge M, Cook G, et al. Positron emission tomography for target volume definition in the treatment of non-small cell lung cancer. Radiother Oncol. 2005;77:1–4
  277. Ford EC, Kinahan PE, Hanlon L, et al. Tumor delineation using PET in head and neck cancers: Threshold contouring and lesion volumes. Med Phys. 2006;33:4280–4288
  278. Ahn PH, Garg MK. Positron emission tomography/computed tomography for target delineation in head and neck cancers. Sem Nucl Med. 2008;38:141–148
  279. Zaidi H. Medical image segmentation: Quo Vadis. Comput Meth Prog Biomed. 2006;84:63–67
  280. Boudraa A, Zaidi H. Image segmentation techniques in nuclear medicine imaging. In:  Zaidi H editors. Quantitative analysis of nuclear medicine images. New York: Springer; 2006;p. 308–357
  281. Erdi Y, Mawlawi O, Larson S, et al. Segmentation of lung lesion volume by adaptive positron emission tomography image thresholding. Radioimmunodetection and radioimmunotherapy of cancer. Princeton, NJ: American Cancer Society; 1997;2505–2509
  282. Daisne JF, Sibomana M, Bol A, et al. Tri-dimensional automatic segmentation of PET volumes based on measured source-to-background ratios: influence of reconstruction algorithms. Radiother Oncol. 2003;69:247–250
  283. Drever L, Roa W, McEwan A, et al. Iterative threshold segmentation for PET target volume delineation. Med Phys. 2007;34:1253–1265
  284. Schinagl DA, Vogel WV, Hoffmann AL, et al. Comparison of five segmentation tools for 18F-fluoro-deoxy-glucose-positron emission tomography-based target volume definition in head and neck cancer. Int J Radiat Oncol Biol Phys. 2007;69:1282–1289
  285. Hatt M, Lamare F, Boussion N, et al. Fuzzy hidden Markov chains segmentation for volume determination and quantitation in PET. Phys Med Biol. 2007;52:3467–3491
  286. Montgomery D, Amira A, Zaidi H. Fully automated segmentation of oncological PET volumes using a combined multiscale and statistical model. Med Phys. 2007;34:722–736
  287. Drever L, Robinson DM, McEwan A, et al. A local contrast based approach to threshold segmentation for PET target volume delineation. Med Phys. 2006;33:1583–1594
  288. Biehl KJ, Kong FM, Dehdashti F, et al. 18F-FDG PET definition of gross tumor volume for radiotherapy of non-small cell lung cancer: is a single standardized uptake value threshold approach appropriate?. J Nucl Med. 2006;47:1808–1812
  289. Jentzen W, Freudenberg L, Eising EG, et al. Segmentation of PET volumes by iterative image thresholding. J Nucl Med. 2007;48:108–114
  290. Ciernik IF, Huser M, Burger C, et al. Automated functional image-guided radiation treatment planning for rectal cancer. Int J Radiat Oncol Biol Phys. 2005;62:893–900
  291. Davis JB, Reiner B, Huser M, et al. Assessment of (18)F PET signals for automatic target volume definition in radiotherapy treatment planning. Radiother Oncol. 2006;80:43–50
  292. Wong CY, Mahajan P, Yan D. Dynamic threshold for radiation target volume by PET/CT. J Nucl Med. 2007;48:849;author reply 847
  293. van Dalen JA, Hoffmann AL, Dicken V, et al. A novel iterative method for lesion delineation and volumetric quantification with FDG PET. Nucl Med Commun. 2007;28:485–493
  294. Aristophanous M, Penney BC, Martel MK, et al. A Gaussian mixture model for definition of lung tumor volumes in positron emission tomography. Med Phys. 2007;34:4223–4235
  295. Schaefer A, Kremp S, Hellwig D, et al. A contrast-oriented algorithm for FDG-PET-based delineation of tumour volumes for the radiotherapy of lung cancer: derivation from phantom measurements and validation in patient data. Eur J Nucl Med Mol Imaging. 2008;35:1989–1999
  296. Breen SL, Publicover J, De Silva S, et al. Intraobserver and interobserver variability in GTV delineation on FDG-PET-CT images of head and neck cancers. Int J Radiat Oncol Biol Phys. 2007;68:763–770
  297. Bosmans G, van Baardwijk A, Dekker A, et al. Intra-patient variability of tumor volume and tumor motion during conventionally fractionated radiotherapy for locally advanced non-small-cell lung cancer: a prospective clinical study. Int J Radiat Oncol Biol Phys. 2006;66:748–753
  298. Coleman RE, Delbeke D, Guiberteau MJ, et al. Concurrent PET/CT with an integrated imaging system: intersociety dialogue from the joint working group of the American College of Radiology, the Society of Nuclear Medicine, and the Society of Computed Body Tomography and Magnetic Resonance. J Nucl Med. 2005;46:1225–1239
  299. Bischof Delaloye A, Carrio I, Cuocolo A, et al. White paper of the European Association of Nuclear Medicine (EANM) and the European Society of Radiology (ESR) on multimodality imaging. Eur J Nuc Med Mol Imaging. 2007;34:1147–1151
  300. Graves EE, Quon A, Loo BW. RT_Image: an open-source tool for investigating PET in radiation oncology. Technol Cancer Res Treat. 2007;6:111–121
  301. Jannin P, Fitzpatrick JM, Hawkes DJ, et al. Validation of medical image processing in image-guided therapy. IEEE Trans Med Imaging. 2002;21:1445–1449
  302. Tomei S, Reilhac A, Visvikis D, et al. Development of a database of realistic simulated whole body 18F-FDG images for lymphoma. Proc IEEE Nuclear Science Symposium and Medical Imaging Conference. Dresden. Germany: IEEE; 2008;4958–4963
  303. Mamede M, El Fakhri G, Abreu-e-Lima P, et al. Pre-operative estimation of esophageal tumor metabolic length in FDG-PET images with surgical pathology confirmation. Ann Nucl Med. 2007;21:553–562
  304. Geets X, Lee J, Bol A, et al. A gradient-based method for segmenting FDG-PET images: methodology and validation. Eur J Nuc Med Mol Imaging. 2007;34:1427–1438
  305. Venel Y, Garhi H, de Muret A, et al. Comparaison de six méthodes de segmentation du volume tumoral sur la 18F-FDG TEP-TDM avec le volume de référence anatomopathologique dans les cancers bronchopulmonaires non à petites cellules. Médecine Nucléaire. 2008;32:339–353
  306. Drever LA, Roa W, McEwan A, et al. Comparison of three image segmentation techniques for target volume delineation in positron emission tomography. J Appl Clin Med Phys. 2007;8:93–109
  307. Visser EP, Philippens MEP, Kienhorst L, et al. Comparison of tumor volumes derived from glucose metabolic rate maps and SUV maps in dynamic 18F-FDG PET. J Nucl Med. 2008;49:892–898
  308. Aerts HJ, Bosmans G, van Baardwijk AA, et al. Stability of (18)F-Deoxyglucose uptake locations within tumor during radiotherapy for NSCLC: a prospective study. Int J Radiat Oncol Biol Phys. 2008;71:1402–1407
  309. Qiao F, Pan T, Clark J, et al. Joint model of motion and anatomy for PET image reconstruction. Med Phys. 2007;34:426–439
  310. Lamare F, Cresson T, Savean J, et al. Respiratory motion correction for PET oncology applications using affine transformation of list mode data. Phys Med Biol. 2007;52:121–140
  311. Rahmim A, Dinelle K, Cheng J-C, et al. Accurate event-driven motion compensation in high-resolution PET incorporating scattered and random events. IEEE Trans Med Imaging. 2008;27:1018–1033
  312. Boutchko R, Reutter B, Gullberg G, et al. Correlating motion of internal organs with the displacements of fiducial markers during respiration. IEEE Nuclear Science Symposium & Medical Imaging Conference. 19–25 October 2008, Dresden, Germany; 2008, 3641–3642.
  313. McQuaid S, Lambrou T, Hutton B. Statistical shape modeling of the diaphragm for application to Rb-82 cardiac PET-CT studies. IEEE Nuclear Science Symposium & Medical Imaging Conference. 19–25 October 2008, Dresden, Germany; 2008, 3651–3655.
  314. Dey J, Segars W, Pretorius P, et al. Estimation and correction of irregular respiratory motion of the heart in presence of partial angle effects due to amplitude binning in SPECT. IEEE Nuclear Science Symposium & Medical Imaging Conference. 19–25 October 2008, Dresden, Germany; 2008, 3656–3662.
  315. Bond S, Kadir T, Hamill J, et al. Automatic registration of cardiac PET/CT for attenuation correction. IEEE Nuclear Science Symposium & Medical Imaging Conference. 19–25 October 2008, Dresden, Germany; 2008, 5512–5517.
  316. Chen S, Tsui B. Accuracy analysis of image-based respiratory motion estimation and compensation in respiratory gated PET reconstruction. IEEE Nuclear Science Symposium & Medical Imaging Conference. 19–25 October 2008, Dresden, Germany; 2008, 4292–4295.
  317. Lucignani G. Respiratory and cardiac motion correction with 4D PET imaging: shooting at moving targets. Eur J Nucl Med Mol Imaging. 2009;36:315–319
  318. Rahmim A, Rousset O, Zaidi H. Strategies for motion tracking and correction in PET. PET Clin. 2007;2:251–266
  319. Guido A, Fuccio L, Rombi B, et al. Combined (18)F-FDG-PET/CT imaging in radiotherapy target delineation for head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2009;73:759–763
  320. Deantonio L, Beldi D, Gambaro G, et al. FDG-PET/CT imaging for staging and radiotherapy treatment planning of head and neck carcinoma. Radiat Oncol. 2008;3:29
  321. Murakami R, Uozumi H, Hirai T, et al. Impact of FDG-PET/CT fused imaging on tumor volume assessment of head-and-neck squamous cell carcinoma: intermethod and interobserver variations. Acta Radiol. 2008;49:693–699
  322. Riegel AC, Berson AM, Destian S, et al. Variability of gross tumor volume delineation in head-and-neck cancer using CT and PET/CT fusion. Int J Radiat Oncol Biol Phys. 2006;65:726–732
  323. Leong T, Everitt C, Yuen K, et al. A prospective study to evaluate the impact of FDG-PET on CT-based radiotherapy treatment planning for oesophageal cancer. Radiother Oncol. 2006;78:254–261
  324. Gondi V, Bradley K, Mehta M, et al. Impact of hybrid fluorodeoxyglucose positron-emission tomography/computed tomography on radiotherapy planning in esophageal and non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2007;67:187–195
  325. Konski A, Doss M, Milestone B, et al. The integration of 18-fluoro-deoxy-glucose positron emission tomography and endoscopic ultrasound in the treatment-planning process for esophageal carcinoma. Int J Radiat Oncol Biol Phys. 2005;61:1123–1128
  326. Vesprini D, Ung Y, Dinniwell R, et al. Improving observer variability in target delineation for gastro-oesophageal cancer - the role of (18F)fluoro-2-deoxy-d-glucose positron emission tomography/computed tomography. Clin Oncol (R Coll Radiol). 2008;20:631–638
  327. Yu HM, Liu YF, Hou M, et al. Evaluation of gross tumor size using CT, (18)F-FDG PET, integrated (18)F-FDG PET/CT and pathological analysis in non-small cell lung cancer. Eur J Radiol. In press.
  328. van Der Wel A, Nijsten S, Hochstenbag M, et al. Increased therapeutic ratio by 18FDG-PET CT planning in patients with clinical CT stage N2-N3M0 non-small-cell lung cancer: a modeling study. Int J Radiat Oncol Biol Phys. 2005;61:649–655
  329. Ceresoli GL, Cattaneo GM, Castellone P, et al. Role of computed tomography and [(18F]) fluorodeoxyglucose positron emission tomography image fusion in conformal radiotherapy of non-small cell lung cancer: a comparison with standard techniques with and without elective nodal irradiation. Tumori. 2007;93:88–96
  330. Ford EC, Lavely WC, Frassica DA, et al. Comparison of FDG-PET/CT and CT for delineation of lumpectomy cavity for partial breast irradiation. Int J Radiat Oncol Biol Phys. 2008;71:595–602
  331. Dolezelova H, Slampa P, Ondrova B, et al. The impact of PET with 18FDG in radiotherapy treatment planning and in the prediction in patients with cervix carcinoma: results of pilot study. Neoplasma. 2008;55:437–441
  332. Lin LL, Mutic S, Low DA, et al. Adaptive brachytherapy treatment planning for cervical cancer using FDG-PET. Int J Rad Oncol Biol Phys. 2007;67:91–96
  333. Bassi MC, Turri L, Sacchetti G, et al. FDG-PET/CT imaging for staging and target volume delineation in preoperative conformal radiotherapy of rectal cancer. Int J Radiat Oncol Biol Phys. 2008;70:1423–1426
  334. Dehdashti F, Grigsby PW, Mintun MA, et al. Assessing tumor hypoxia in cervical cancer by positron emission tomography with 60Cu-ATSM: relationship to therapeutic response-a preliminary report. Int J Radiat Oncol Biol Phys. 2003;55:1233–1238
  335. Popperl G, Gotz C, Rachinger W, et al. Serial O-(2-[(18)F]fluoroethyl)-L-tyrosine PET for monitoring the effects of intracavitary radioimmunotherapy in patients with malignant glioma. Eur J Nucl Med Mol Imaging. 2006;33:792–800

 Supported by the Swiss National Science Foundation under grant SNSF 3152A0-102143.

PII: S1076-6332(09)00144-5

doi: 10.1016/j.acra.2009.02.014

Academic Radiology
Volume 16, Issue 9 , Pages 1108-1133 , September 2009

Article Tools

* Image Usage & Resolution